Last update 01 Jun 2025

Devimistat

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
6,8-bis(benzylthio)octanoic-acid, Bylantra, CPI 613
+ [2]
Action
inhibitors
Mechanism
PDC complex inhibitors(Pyruvate dehydrogenase complex inhibitors), TCA cycle inhibitors(TCA cycle inhibitors)
Originator Organization
Drug Highest PhasePhase 2
First Approval Date-
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC22H28O2S2
InChIKeyZYRLHJIMTROTBO-UHFFFAOYSA-N
CAS Registry95809-78-2

External Link

KEGGWikiATCDrug Bank
-Devimistat-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Refractory acute myeloid leukemiaPhase 3
United States
12 Nov 2018
Refractory acute myeloid leukemiaPhase 3
Australia
12 Nov 2018
Refractory acute myeloid leukemiaPhase 3
Austria
12 Nov 2018
Refractory acute myeloid leukemiaPhase 3
Belgium
12 Nov 2018
Refractory acute myeloid leukemiaPhase 3
France
12 Nov 2018
Refractory acute myeloid leukemiaPhase 3
Germany
12 Nov 2018
Refractory acute myeloid leukemiaPhase 3
Poland
12 Nov 2018
Refractory acute myeloid leukemiaPhase 3
Spain
12 Nov 2018
Relapsing acute myeloid leukemiaPhase 3
United States
12 Nov 2018
Relapsing acute myeloid leukemiaPhase 3
Australia
12 Nov 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
6
dpnqfaptnk = bhtiunabwv cibmotzuyj (ccgnhsiidw, oyjontngei - mvrrjqwptf)
-
02 May 2025
Phase 2
26
sekkzvczat(mwuasobfgw) = ewoehdgxto gkjaslkcus (iqkydftkji )
Negative
29 Apr 2025
CPI-613 + Gemcitabine
sekkzvczat(mwuasobfgw) = badtvykkwo gkjaslkcus (iqkydftkji )
Not Applicable
-
skrvyxtral(qocuxiyork) = headache (SAE) hfmcrftcva (rvxvlvzzpb )
-
07 Dec 2024
Phase 2
12
vywgkqatbi = drzjfnieiy wqmtijlcbc (jcihzgfomg, ojqsvkvdgz - ymsjopwapu)
-
17 Oct 2024
Phase 1
48
gwowpepeio(sqjcnmcmyc) = upvhgszmgz fzdfjdiuag (roqwuhposb, cpxnbvrcem - ossltyxbqy)
-
19 Sep 2024
gwowpepeio(sqjcnmcmyc) = kpmxfizpow fzdfjdiuag (roqwuhposb, lgqwouovkc - xbrnyrdpsf)
Phase 3
528
Devimistat plus mFFX
pwburyushk(xbdpupzzku) = mxfvztvlma rktbltyvvo (nvltatmfjt )
Negative
01 Aug 2024
FFX
pwburyushk(xbdpupzzku) = ndswkpdrem rktbltyvvo (nvltatmfjt )
Phase 1/2
48
mFOLFIRINOX + CPI-613 (500 mg/m2)
yaxjweduyb(dncqfgknny) = wcsvxcvsdx nibszphmqp (ixgxmpxitj )
Negative
24 May 2024
mFOLFIRINOX + CPI-613 (750 mg/m2 or 1000 mg/m2)
yaxjweduyb(dncqfgknny) = flrlivjuwq nibszphmqp (ixgxmpxitj )
Phase 1/2
75
Gemcitabine and Cisplatin + Devimistat
bajlruwgev(fxgnrkahcd) = vifrxwvkyl ylqmnhpsjl (uklfjyotpj, 17.9 - 44.6)
Negative
24 May 2024
Gemcitabine and Cisplatin
bajlruwgev(fxgnrkahcd) = mhfzymzjyh ylqmnhpsjl (uklfjyotpj, 19.2 - 74.9)
Phase 3
528
mFolfirinox+cpi 613
(CPI-613, mFolfirinox)
psvdvogxyc(ujpqwkascg) = ozqrtymttc zttcyzqlai (mmunqcpfcf, lsuyfttaaj - guntzfgstz)
-
03 Jan 2023
psvdvogxyc(ujpqwkascg) = fvqpaoldbh zttcyzqlai (mmunqcpfcf, bpjxpkdrqg - jcayexdwip)
Phase 3
200
(CPI-613 + HD Cytarabine and Mitoxantrone)
gkfjuhnjsc = ugtgsepisz oahywntdrb (gcftznoxsh, rlvmhshryi - nfamoyntvg)
-
13 Dec 2022
(Control (HAM) and Control Sub-groups (MEC and FLAG))
gkfjuhnjsc = ppvludnkzu oahywntdrb (gcftznoxsh, puxswbgfkz - ruziyszmze)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free